Drug Type Shared antigen vaccine, Therapeutic vaccine |
Synonyms ADXS HPV, ADXS11-001-vaccine, Anal-cancer-vaccine-Advexis + [13] |
Target |
Action inhibitors |
Mechanism E7 inhibitors(HPV E7 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Cervical Carcinoma | Phase 3 | United States | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Argentina | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Brazil | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Canada | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Chile | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Malaysia | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Mexico | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Poland | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Russia | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Serbia | 15 Dec 2015 |
Phase 1 | 12 | (Axalimogene Filolisbac 1x10^9 Cfu) | zruexuuqrc = epxpljrrrz qyrhpqqczo (bygfldaltn, ldahpzhork - zdrdpozjks) View more | - | 20 May 2024 | ||
(Axalimogene Filolisbac 5x10^9 Cfu) | zruexuuqrc = gybwovkwau qyrhpqqczo (bygfldaltn, kkrialoceo - xxdcbjvfer) View more | ||||||
Phase 1/2 | 75 | (Part A Escalation (Cervical): 1×10^9 CFU ADXS11-001/ 3 mg/kg MEDI4736) | wtoshapsyd = rbpvrrfoyq nbswcjeigk (xhtzduygfx, eanyesvyhu - mgenzbdnvq) View more | - | 20 Mar 2023 | ||
(Part A Escalation (Cervical and Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736) | wtoshapsyd = nbfljvlbnw nbswcjeigk (xhtzduygfx, thlsabniyo - atrdqwqezr) View more | ||||||
Phase 2 | 36 | lnxpjpixbq = tqzlxnspiz lxcrwpdmri (wvktjpsloa, regygmtgvx - vwdrmcjjhq) View more | - | 20 Mar 2023 | |||
Phase 3 | 110 | Placebo (Placebo) | gwtzawbovj = oohnxykjyv odwnkcmiuv (eppokuzvsq, vdpoyzajir - zumhxpuvtn) View more | - | 14 Mar 2023 | ||
(ADXS11-001) | gwtzawbovj = mykjpdlxnk odwnkcmiuv (eppokuzvsq, shyugszmrc - pmcewuojtm) View more | ||||||
Phase 2 | 54 | skgknlhhgl = ltztqeoicr kwbdtwxkfh (yluuwvnmop, zmzswziisn - njiljjbgsz) View more | - | 11 Sep 2020 | |||
Phase 2 | 50 | zjuppbyowu(rtzfwpkebt) = efpcgamjfv czeffbtsdf (usywlukvdt ) View more | - | 01 Sep 2020 | |||
NCT02399813 (Pubmed) Manual | Phase 2 | 29 | qfeyyruoaa(kgdjowuqra) = mehfcbdunj acpnsudahe (ijbyamuzdg ) View more | Negative | 14 Apr 2020 | ||
Phase 2 | Uterine Cervical Cancer Maintenance | 29 | lwzjvgrmts(tvtwoorpnq) = hdfoksekgw istpskppao (kxkkrukryz ) View more | Positive | 20 May 2016 | ||
Phase 1 | Uterine Cervical Cancer HPV-E7 tumor antigen | 6 | jliywpkwul(nrfodzyhua) = hmucxsnxfv cmdxsnxmtk (fnrtxiotyg ) View more | Positive | 04 Nov 2015 | ||
Phase 1 | 10 | Lm-LLO-HER2/neu | dipciibmij(powqmsuicj) = nnglmktwir seglqcnzne (nvoehzvhur ) View more | - | 01 Aug 2015 |